Mass spectrometry coupled with liquid chromatography (LC-MS/MS) is transforming clinical research by enabling precise identification and quantification of disease-specific biomarkers. When integrated across omics workflows—metabolomics, lipidomics, and proteomics—this technology delivers unmatched sensitivity, specificity, and multiplexing capabilities. These advantages are helping researchers uncover the molecular underpinnings of disease and personalize treatment strategies with greater confidence.

Join leading experts in clinical metabolomics—Professor Martin Giera (Leiden University Medical Center) and Professor Antonin Lamazière (Sorbonne University and Saint Antoine’s Hospital)—as they explore how LC-MS/MS-based omics technologies are advancing disease mechanism profiling.

What you'll learn

• Best practices for LC-MS/MS assay development to accurately identify and quantify disease-related biomarkers in clinical samples
• Innovative metabolomic and lipidomic workflows powered by LC-MS/MS that reveal indicators and deepen understanding of disease mechanisms
• Breakthroughs in LC-MS/MS instrumentation and bioinformatics that enhance sensitivity, throughput, and reliability for biomarker discovery
• Advanced MS techniques for mapping lipidomic and metabolomic shifts, offering insights into disease onset and progression

Speakers

Martin Giera

Professor for Translational Metabolomics and Lipidomics,

Leiden University Medical Center

Antonin Lamazière

Professor and Hospital Practitioner (Sorbonne University's Faculty of Medicine) and Department Head Department of Clinical Metabolomics (Saint Antoine’s Hospital),

Sorbonne University and Saint Antoine’s Hospital